Molecular insight into atypical instability behavior of fixed-dose combination containing amlodipine besylate and Losartan potassium (cas 12475-99-8)

Add time:08/19/2019    Source:sciencedirect.com

Combination therapy with the use of fixed-dose combinations (FDCs) is evincing increasing interest of prescribers, manufacturers and even regulators, evidently due to the primary benefit of improved patient compliance. However, owing to potential of drug-drug interaction, FDCs require closer scrutiny with respect to their physical and chemical stability. Accordingly, the purpose of the present study was to explore stability behavior of a popular antihypertensive combination of amlodipine besylate (AML) and losartan potassium (LST). Physical mixtures of the two drugs and multiple marketed formulations were stored under accelerated conditions of temperature and humidity (40 °C/75% RH) in a stability chamber and samples were withdrawn after 1 and 3 months. The physical changes were observed visibly, while chemical changes were monitored by HPLC employing a method that could separate the two drugs and all other components present. The combination revealed strong physical instability and also chemical degradation of AML in the presence of LST. Interestingly, three isomeric interaction products of AML were formed in the combination, which otherwise were reported in the literature to be generated on exposure of AML free base above its melting point. The same unusual products were even formed when multiple marketed FDCs were stored under accelerated conditions outside their storage packs. However, these were absent when AML alone was stored in the same studied conditions. Therefore, reasons for physical and chemical incompatibility and the mechanism of degradation of AML in the presence of LST were duly explored at the molecular level. The outcomes of the study are expected to help in development of stable FDCs of the two drugs.

We also recommend Trading Suppliers and Manufacturers of Losartan potassium (cas 12475-99-8). Pls Click Website Link as below: cas 12475-99-8 suppliers

Prev:Formulation and evaluation of sublingual tablets of Losartan potassium (cas 12475-99-8)
Next:Synthesis of 5-hydroxymethylfurfural from fructose catalyzed by phosphotungstic acid)